The effects of probiotic and prebiotic in Nonalcoholic fatty liver disease.

The effects of probiotic, prebiotic and concomitant supplementation of probiotic, Prebiotic on the oxidative stress, inflammatory and insulin resistance indices, lipid profile and liver function in non-alcoholic fatty liver. patients.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201301223140N6

Enrollment

Registered

2014-01-16

Start date

2013-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver. Other diseases of liver

Interventions

Intervention 1: Intervention groups: Group1 treated with 1 gr of probiotic capcul (107 Bifidobacterium longum and Lactobacillus acidophilus) and 5 gr of prebiotic plasebo (multodextrose) twice a day f

Treatment - Drugs

Intervention groups: Group1 treated with 1 gr of probiotic capcul (107 Bifidobacterium longum and Lactobacillus acidophilus) and 5 gr of prebiotic plasebo (multodextrose) twice a day for 3 months. Gro

Control group: Group 4 treated with 1 gr of probiotic placebo (powder milk free fat and sugar) and 5 gr of prebiotic placebo (multodextrose) twice a day for 3 months.

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: non-alcoholic fatty liver patients with age between 20-60 (both of gender) years agreed to participate the study. Exclusion criteria: Pregnancy and lactation; viral hepatitis B and C; cardiovascular; thyroid; renal; autoimmune and inflammatory disorders; hemochromatosis; Wilson disease; usage of alcohol and supplements of A,E,C.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
AST. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;ALT. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;?GT. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;ALP. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;ALB. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;BIL. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;TC. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;TG. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;LDL. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;HDL. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;Hs-CRP. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;TNF-a. Timepoint: Befor and after intervention. Method of measurement: Serum of blood,ELISA.;IL-6. Timepoint: Befor and after intervention. Method of measurement: Serum of blood,ELISA.;MDA. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;TAC. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;Insulin. Timepoint: Befor and after intervention. Method of measurement: Serum of blood,ELISA.;FBS. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;HOMA-IR. Timepoint: Befor and after intervention. Method of measurement: srrum insulin*FBS/405.	—

Measure

Time frame

AST. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;ALT. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;?GT. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;ALP. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;ALB. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;BIL. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;TC. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;TG. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;LDL. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;HDL. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;Hs-CRP. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;TNF-a. Timepoint: Befor and after intervention. Method of measurement: Serum of blood,ELISA.;IL-6. Timepoint: Befor and after intervention. Method of measurement: Serum of blood,ELISA.;MDA. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;TAC. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;Insulin. Timepoint: Befor and after intervention. Method of measurement: Serum of blood,ELISA.;FBS. Timepoint: Befor and after intervention. Method of measurement: serum of blood, by outoanalyzer.;HOMA-IR. Timepoint: Befor and after intervention. Method of measurement: srrum insulin*FBS/405.

—

Secondary

Measure	Time frame
Body mass index. Timepoint: Befor and after intervention. Method of measurement: W/H2.;WRT. Timepoint: Befor and after intervention. Method of measurement: waist to hip ratio.;Intake micro and macro nutrients. Timepoint: Befor and after intervention. Method of measurement: Three days weighing food questionnaires.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Javadi

Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz

javadi.biochem@gmail.com+98 41 1335 2292

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026